Notice of NIDA Participation in PAR-20-039, Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)”

Notice Number: NOT-DA-20-025

Key Dates
Release Date: December 10, 2019

Related Announcements
PAR-20-039

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating in PAR-20-039 “Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)”.

The following sections have been updated to reflect the participation of NIDA in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of General Medical Sciences (NIGMS)
National Institute on Aging (NIA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute of Environmental Health Sciences ( NIEHS )
National Heart, Lung and Blood Institute ( NHLBI )

National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.859; 93.866; 93.853; 93.855; 93.847; 93.121; 93.173, 93.113, 93.233, 93.837, 93.838, 93.839, 93.840; 93.279

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Albert Avila, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov

Financial/Grants Management Contact(s)

Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159
Email: pfleming@nida.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Albert Avila, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov